

## **Product datasheet for TL320359**

## **OriGene Technologies, Inc.** 9620 Medical Center Drive, Ste 200

Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

## **FOXO3 Human shRNA Plasmid Kit (Locus ID 2309)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** FOXO3 Human shRNA Plasmid Kit (Locus ID 2309)

Locus ID: 2309

Synonyms: AF6q21; FKHRL1; FKHRL1P2; FOXO2; FOXO3A

**Vector:** pGFP-C-shLenti (TR30023) **E. coli Selection:** Chloramphenicol (34 ug/m

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell Puromycin

Selection:

Format:

Lentiviral plasmids

**Components:** FOXO3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 2309).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 001455, NM 201559, NM 201559.1, NM 201559.2, NM 001455.1, NM 001455.2,

NM 001455.3, BC021224, BC021224.2, BC068552, BC020227, BC045800, NM 201559.3

UniProt ID: <u>043524</u>

**Summary:** This gene belongs to the forkhead family of transcription factors which are characterized by a

distinct forkhead domain. This gene likely functions as a trigger for apoptosis through

expression of genes necessary for cell death. Translocation of this gene with the MLL gene is associated with secondary acute leukemia. Alternatively spliced transcript variants encoding

the same protein have been observed. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).